• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
FMTX

FMTX

Forma Therapeutics Holdings, Inc.

NASDAQHealthcareBiotechnologyUS

USD20.01

+0.00 (+0.00%)

Company Profile

CEO

Frank D. Lee

IPO Date

2020-06-19

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$20.00

Prev. Close

$20.01

Day Low

$19.98

Day High

$20.01

52W Low

$4.95

52W High

$20.28

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

22.8%

Avg Negative

3.0%

Avg Neutral

74.2%

News Feed

Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D.

Business Wire·6/14/2021·↑ positive

Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease

Benzinga·6/11/2021·↑ positive

Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress

Business Wire·6/11/2021·↑ positive

Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

Business Wire·5/20/2021·↑ positive

Forma Therapeutics to Participate in Upcoming Investor Conferences

Business Wire·5/17/2021·↑ positive

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/14/2021·↓ negative

Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Business Wire·5/14/2021·↑ positive

Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

Business Wire·5/6/2021·↑ positive

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/30/2021·↓ negative

Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

Benzinga·3/30/2021·↑ positive